[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"petct-imaging\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:petct-imaging":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,67,91],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100617948","phase-2-a-pilot-study-to-correlate-4-18f--fluoro-1-naphthol-18f-4fn-petct-imaging-with-chronic-graft-versus-host-disease-manifestations-100617948",false,"NCT07325253","A Pilot Study to Correlate 4-18F- Fluoro-1-naphthol 18F-4FN PET\u002FCT Imaging With Chronic Graft Versus Host Disease Manifestations","Eligibility Criteria\n\n1. Chronic GVHD involving the joints, defined as any limitation of range of motion measured by Photographic Range Of Motion (PROM). Criteria can be found at (Jagasia, et al. 2015).\n2. Able to give written informed consent.\n3. ≥18 years of age\n4. Creatinine clearance ≥ 30 mL\u002Fmin\u002F1.73m2\n5. Non-joint chronic GVHD diagnostic \u002F distinctive features are allowed.\n6. Subjects may be planned to receive a new systemic therapy for chronic GVHD\n7. Prior\u002Fcontinuing systemic therapy for chronic GVHD is allowed\n8. KPS ≥ 20\n9. Ability to understand and the willingness to sign a written informed consent document.\n10. The effects of the study agent on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. (Refer to Pregnancy Assessment Policy MD Anderson Institutional Policy # CLN1114). This includes all female participants, between the onset of menses (as early as 8 years of age) and 55 years unless the participant presents with an applicable exclusionary factor which may be one of the following:\n\n    * Postmenopausal (no menses in greater than or equal to 12 consecutive months).\n    * History of hysterectomy or bilateral salpingo-oophorectomy.\n    * Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).\n    * History of bilateral tubal ligation or another surgical sterilization procedure.\n\n      * Approved methods of birth control are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject\u002FPartner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.\n11. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of study agent administration.\n\nExclusion Criteria\n\n1. Unable to comply with all study procedures (for example, participants who are unable to come to all follow up visits because they live far away from the transplant center)\n2. Pregnant or lactating women: pregnant women are excluded from this study because the effects of \\[18F\\]4FN in pregnancy are not known.\n3. Subjects with contraindications to the use of \\[18F\\]4FN including confirmed allergy.\n4. Participants with a body weight of 400 pounds or more, or a body habitus which precludes their entry into the bore of the PET\u002FCT scanner, because the hardware is not intended to support that weight.\n5. Any additional medical condition, serious concurrent illness, or other extenuating circumstance that, in the opinion of the investigator, may significantly interfere with study compliance.\n6. Children below the age of 18 are excluded because of the unknown but potential risks of administration of radiopharmaceuticals to minors.","ALL","18 Years",{"count":18,"type":19},16,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","To study the safety and possible side effects of using the imaging agent 4-\\[18F\\]Fluoro-1-Naphthol (also called \\[18F\\]4FN) in PET\u002FCT scans for participants with chronic GVHD.",[25,26,27],"Pilot Study","PET\u002FCT Imaging","Host Disease Manifestation","RECRUITING","2026-08-18",{"date":31,"type":32},"2026-08-20","ACTUAL",{"date":34,"type":32},"2025-11-18",{"date":36,"type":19},"2030-01-03",{"name":38,"class":39},"M.D. Anderson Cancer Center","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":20,"phases":50,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":4},"100646924","phase-2-comparative-f-fdg-and-ga-my6349-petct-imaging-for-assessing-trop2-adc-therapeutic-efficacy-in-egfr-tki-resistant-advanced-nsclc-100646924","NCT07685197","Comparative ¹⁸F-FDG and ⁶⁸Ga-MY6349 PET\u002FCT Imaging for Assessing TROP2 ADC Therapeutic Efficacy in EGFR-TKI Resistant Advanced NSCLC","Efficacy Evaluation of TROP2 ADC Therapy in Patients With Advanced\u002FMetastatic NSCLC Resistant to EGFR-TKIs: A Comparative Imaging Study of ¹⁸F-FDG and ⁶⁸Ga-MY6349 PET\u002FCT","Inclusion Criteria:\n\n* Aged ≥18 years at the time of signing the informed consent form, with no restriction on gender.\n* Histologically or cytologically confirmed non-squamous non-small cell lung cancer (NSCLC), classified as locally advanced Stage IIIB\u002FIIIC or metastatic Stage IV NSCLC (per the 8th edition of UICC\u002FAJCC TNM staging system for lung cancer), and not eligible for curative resection and\u002For definitive radiotherapy (with or without concurrent chemotherapy).\n* Presence of EGFR sensitizing mutations (exon 19 deletion or exon 21 L858R point mutation).\n* Subjects who have received first-line third-generation EGFR-TKI therapy with documented treatment failure. For subjects previously treated with third-generation EGFR-TKIs in adjuvant, neoadjuvant or consolidation settings, such TKI therapy will be regarded as first-line treatment for locally advanced or metastatic disease if disease progression occurs within ≤6 months after the last dose.\n* At least one measurable lesion as defined by RECIST v1.1; previously irradiated lesions shall not be selected as target lesions. Subjects with only cutaneous or osseous lesions are not eligible for enrollment.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days prior to study drug administration.\n* Estimated life expectancy ≥12 weeks.\n* Adequate organ and bone marrow function (no blood transfusion, recombinant thrombopoietin or colony-stimulating factor administered within 2 weeks before dosing), defined as follows:\n\n  1. Hematology: Absolute neutrophil count (NEUT#) ≥1.5×10⁹\u002FL; platelets (PLT) ≥100×10⁹\u002FL; hemoglobin ≥90 g\u002FL.\n  2. Hepatic function: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN; total bilirubin (TBIL) ≤1.5×ULN; albumin ≥30 g\u002FL. For subjects with hepatic metastases at baseline, ALT and AST ≤5×ULN, TBIL ≤3×ULN.\n  3. Renal function: Creatinine clearance ≥50 mL\u002Fmin (calculated using the standard Cockcroft-Gault formula).\n  4. Coagulation function: International normalized ratio (INR), activated partial thromboplastin time (APTT) and prothrombin time (PT) ≤1.5×ULN.\n* Females of childbearing potential and male subjects whose partners are of childbearing potential must agree to use effective medical contraception from the date of informed consent signature through 6 months after the last study drug administration.\n* The subject voluntarily participates in this study, signs the informed consent form, and is able to comply with all protocol-specified visits and relevant procedures.\n\nExclusion Criteria:\n\n* Tumor histology or cytology confirms mixed components including small cell lung cancer, neuroendocrine carcinoma, carcinosarcoma, or squamous cell carcinoma.\n* Subjects with known leptomeningeal metastases, brainstem metastases, spinal cord metastases\u002Fcompression, or symptomatic unstable central nervous system (CNS) metastases are excluded unless they are off steroid therapy and maintain stable neurological status for at least two weeks after completion of definitive radiotherapy and steroid tapering.\n* Prior systemic anti-tumor therapy for locally advanced or metastatic non-squamous NSCLC other than third-generation EGFR-TKIs (e.g., chemotherapy, immunotherapy).\n* Previous treatment with any TROP2-targeted agents or therapeutics containing topoisomerase I inhibitors, including antibody-drug conjugates (ADCs), whether administered in adjuvant, neoadjuvant, or metastatic disease settings.\n* Thoracic radiotherapy with a cumulative dose \\>30 Gy delivered within 6 months prior to the first dose; non-thoracic or extended-field radiotherapy with a cumulative dose \\>30 Gy administered within 4 weeks prior to the first dose. Palliative radiotherapy for symptom control is permitted only if completed at least 2 weeks before study drug initiation.\n* History of another primary malignant tumor within 3 years before the first dose, excluding malignancies cured by local therapy such as basal cell carcinoma of the skin, cutaneous squamous cell carcinoma, and cervical carcinoma in situ.\n* Presence of any of the following cardiovascular or cerebrovascular diseases or risk factors:\n\n  1. Myocardial infarction, unstable angina, acute or persistent myocardial ischemia, New York Heart Association (NYHA) Class III\u002FIV heart failure, symptomatic or poorly controlled severe arrhythmia, cerebrovascular accident, transient ischemic attack, or other severe cardiovascular\u002Fcerebrovascular events within 6 months before dosing.\n  2. Medical history of myocarditis, primary cardiomyopathy, or specific cardiomyopathies.\n  3. Deep vein thrombosis, peripheral arterial thromboembolism, pulmonary embolism, or other severe thromboembolic events within 3 months prior to dosing (subjects may be enrolled if stably treated with low-molecular-weight heparin or equivalent anticoagulants for ≥2 weeks).\n  4. Life-threatening major vascular diseases including aortic aneurysm or aortic dissection requiring surgical intervention within 6 months before dosing.\n  5. Corrected QT interval (QTcF) \\>470 ms.\n* Uncontrolled systemic diseases as judged by the investigator:\n\n  1. Poorly controlled diabetes mellitus (two consecutive fasting blood glucose readings ≥10 mmol\u002FL).\n  2. Uncontrolled hypertension (systolic blood pressure \\>160 mmHg and\u002For diastolic blood pressure \\>100 mmHg).\n  3. Clinically symptomatic pleural effusion, pericardial effusion, or ascites requiring repeated drainage more than once per week.\n* History of steroid-dependent non-infectious interstitial lung disease (ILD) or non-infectious pneumonitis; active ILD or non-infectious pneumonitis at screening; or suspicious ILD\u002Fpneumonitis that cannot be ruled out by screening imaging.\n* Documented severe dry eye syndrome, severe meibomian gland disease and\u002For blepharitis, or history of severe corneal disorders that hinder or delay corneal wound healing.\n* Clinically significant severe pulmonary impairment secondary to concurrent lung disorders, including but not limited to underlying lung diseases (e.g., severe asthma, advanced chronic obstructive pulmonary disease, restrictive lung disease within 3 months prior to dosing); autoimmune, connective tissue, or inflammatory disorders with pulmonary involvement (rheumatoid arthritis, Sjögren's syndrome, sarcoidosis, etc.); or prior pneumonectomy.\n* Active chronic inflammatory bowel disease, gastrointestinal obstruction, severe ulceration, gastrointestinal perforation, intra-abdominal abscess, or acute gastrointestinal hemorrhage.\n* Active gastrointestinal disorders or other conditions that substantially alter the absorption, distribution, metabolism, or excretion of oral study drugs (e.g., refractory nausea and vomiting, chronic gastrointestinal disease, inability to swallow oral medication, history of extensive intestinal resection).\n* Risk of esophagotracheal or esophagopleural fistula; tumor invasion or compression of vital adjacent organs and vessels (heart, esophagus, superior vena cava, etc.) accompanied by relevant clinical manifestations such as superior vena cava syndrome.\n* Toxicities from prior anti-tumor therapy that have not resolved to Grade ≤1 per NCI CTCAE v5.0 or the thresholds specified in eligibility criteria (alopecia, fatigue, and other toxicities judged low-risk by the investigator are exempted).\n* Severe infection occurring within 4 weeks before dosing, including but not limited to complications requiring hospitalization, sepsis, or severe pneumonia; active infection requiring systemic antimicrobial therapy within 2 weeks before dosing.\n* Confirmed active pulmonary tuberculosis. Subjects with suspected active tuberculosis must undergo clinical examinations to rule out infection before enrollment.\n* Active hepatitis B (HBsAg-positive with HBV-DNA ≥500 IU\u002FmL or above the lower limit of quantification, whichever is higher); active hepatitis C (anti-HCV positive with HCV-RNA above the lower limit of quantification); or concurrent HBV and HCV co-infection.\n* Positive human immunodeficiency virus (HIV) serology or history of acquired immunodeficiency syndrome (AIDS); known active syphilis infection.\n* History of allogeneic solid organ transplantation or allogeneic hematopoietic stem cell transplantation.\n* Major surgery performed within 4 weeks prior to dosing or major surgery planned during study participation.\n* Known hypersensitivity to the study drug or any of its excipients (including polysorbate 20); history of severe hypersensitivity reactions to other biologic agents.\n* Non-specific immunomodulatory therapy (including but not limited to interferon, IL-2) or proprietary Chinese medicines with approved anti-tumor indications administered within 2 weeks before dosing.\n* Current use (or inability to discontinue prior to the first study dose) of drugs or herbal supplements that are strong cytochrome P450 (CYP) 3A4 inducers, with a minimum 3-week washout period required. All subjects shall avoid concomitant use of any CYP3A4-inducing medications, herbal supplements, and\u002For relevant foods throughout the study.\n* Live vaccine administered within 30 days before dosing or planned live vaccination during study participation.\n* Rapid clinical deterioration during screening, such as marked decline in performance status.\n* Pregnant or breastfeeding women.\n* Local or systemic non-malignant diseases, or tumor-induced diseases\u002Fsymptoms that carry high medical risks and\u002For cause uncertainty in survival assessment, such as leukemoid reaction, cachexia, etc.\n* Any medical condition that, in the investigator's opinion, may confound the evaluation of the study drug, compromise subject safety, interfere with the interpretation of study results, or render the subject unsuitable for trial participation.",{"count":49,"type":19},100,[22],"The primary objective is to evaluate the correlation between ⁶⁸Ga-MY6349 PET\u002FCT-derived metrics reflecting tumoral TROP2 expression activity (including SUVmax, SUVmean, MTV, TLG, etc.) and progression-free survival (PFS) assessed per RECIST v1.1. This study plans to enroll 100 EGFR-mutant patients with advanced non-small cell lung cancer (NSCLC) who have developed resistance following first-line therapy with third-generation EGFR-TKIs.\n\nScreening assessments will be completed within 28 days after patients sign the informed consent form. Eligible subjects will undergo a baseline ⁶⁸Ga-MY6349 PET\u002FCT scan prior to study drug administration, with imaging coverage from mid-thighs to the vertex of the skull. All subjects will receive a ¹⁸F-FDG PET\u002FCT scan within 14 days after the ⁶⁸Ga-MY6349 PET\u002FCT. For patients who have undergone ¹⁸F-FDG PET\u002FCT within 14 days before the ⁶⁸Ga-MY6349 scan, the existing imaging data can be used for diagnostic performance evaluation, and repeat ¹⁸F-FDG PET\u002FCT is not required.\n\nSubsequently, subjects will receive monotherapy with sacituzumab govitecan at a dose of 5 mg\u002Fkg via intravenous infusion (IV) on Day 1 of each cycle, administered every 2 weeks (Q2W). Treatment will continue until investigator-confirmed radiological disease progression, intolerable adverse toxicity, voluntary treatment discontinuation by the subject, or any other protocol-specified treatment discontinuation criterion, whichever occurs first.\n\nAt 3 months after initiation of sacituzumab govitecan treatment, subjects will repeat the ⁶⁸Ga-MY6349 PET\u002FCT scan (coverage: mid-thighs to vertex), followed by a ¹⁸F-FDG PET\u002FCT examination within 14 days thereafter.\n\nEligible subjects will receive regular tumor assessments in accordance with RECIST v1.1. Within 48 weeks after the first dose, imaging-based tumor assessments will be performed every 6 weeks (±7 days). At Week 12 (±1 week), paired ⁶⁸Ga-MY6349 and ¹⁸F-FDG PET\u002FCT scans will be conducted without routine diagnostic CT. After Week 48, tumor assessments will be scheduled every 12 weeks (±7 days) until radiological disease progression, initiation of subsequent anti-tumor therapy, withdrawal of informed consent, loss to follow-up, death, or study termination by the sponsor, whichever comes first. Imaging assessments will follow the predetermined schedule regardless of dose delays or dose modifications.\n\nAfter the first documented complete response (CR) or partial response (PR), response confirmation imaging must be conducted no less than 4 weeks (28 days) later. For subjects discontinuing treatment for reasons other than radiological progression, death or loss to follow-up, if more than 4 weeks have passed since the last imaging evaluation, repeat imaging will be performed at the End-of-Treatment (EOT) visit. Subsequent imaging assessments will be conducted per schedule to the greatest extent feasible until radiological disease progression, initiation of new anti-tumor therapy, consent withdrawal, loss to follow-up, death, or sponsor-initiated study termination, whichever occurs earliest.\n\nAll ⁶⁸Ga-MY6349 PET\u002FCT images will be blindly and independently reviewed by two experienced nuclear medicine physicians who are not involved in this clinical trial (without access to any clinical data) to identify positive NSCLC lesions, as well as lesion location and count. In case of disagreement between the two independent readers regarding the presence of positive lesions, a blinded arbitration review by a senior nuclear medicine expert will be activated, and the arbitrator's reading results will serve as the final conclusion. All ¹⁸F-FDG PET\u002FCT images will undergo single blinded independent review by one nuclear medicine physician.\n\nUpon completion of treatment, all subjects will complete safety follow-up regardless of whether they receive subsequent anti-tumor therapy. Telephone-based survival follow-up visits will be conducted every 3 months (±14 days) after the last dose of study treatment to collect survival status and information on subsequent anti-tumor treatments, until subject withdrawal, loss to follow-up, death, or study closure, whichever occurs first.",[53,54,55,56,26],"NSCLC","EGFR Activating Mutation","EGFR-TKI-resistant Non-Small Cell Lung Cancer","Trop2","NOT_YET_RECRUITING","2026-06-30",{"date":60,"type":32},"2026-07-06",{"date":62,"type":19},"2026-07",{"date":64,"type":19},"2028-07",{"name":66,"class":39},"Zhou Chengzhi",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":74,"sex":15,"minAge":16,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":20,"phases":78,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":40},"100586155","study-on-c-met-targeted-petct-imaging-in-nsclc-100586155","NCT06911697","Study on c-Met Targeted PET\u002FCT Imaging in NSCLC","In Vivo Detection of c-Met Activation Status by Specific PET\u002FCT Imaging Based on 18F Labeled Small Molecule TKI","Inclusion Criteria:\n\n1. Age range 18-75 years, open to both male and female participants;\n2. Normal hepatic\u002Frenal function and cardiac function;\n3. Expected survival of at least 12 weeks;\n4. Good adherence to follow-up;\n5. Presence of at least one measurable target lesion according to RECIST 1.1 criteria;\n6. Women of childbearing age (15-49 years) must undergo a pregnancy test within seven days prior to the commencement of the study and test negative; sexually active male and female participants must agree to utilize effective contraception to prevent pregnancy during the study and for three months following the final examination;\n7. Patients for whom a clinical physician recommends PET\u002FCT scans for the diagnosis and staging of tumors;\n8. Participants must fully understand and voluntarily agree to participate in the study, and must sign an informed consent form.\n\nExclusion Criteria:\n\n1. Severe abnormalities in liver and renal function and blood counts;\n2. Patients planning to conceive;\n3. Pregnant or lactating women;\n4. Individuals unable to lie flat for thirty minutes;\n5. Individuals who refuse to participate in this clinical study;\n6. Individuals suffering from claustrophobia or other psychiatric disorders;\n7. Other situations deemed unsuitable for trial participation by the researchers.",true,"75 Years",{"count":77,"type":19},88,[79],"NA","The investigators developed a 18F labeled small molecule, 18F-TSPF, based on c-Met TKI, as a targeted molecular imaging agent for noninvasive and repeatable detecting c-Met activation status.",[26,53],"2025-03-28",{"date":84,"type":32},"2025-04-04",{"date":86,"type":32},"2023-10-26",{"date":88,"type":19},"2025-06-28",{"name":90,"class":39},"Xilin Sun",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":20,"phases":99,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":40},"100481440","early-phase-1-68ga-rm26-rgd-petct-imaging-in-the-grpr-and-v3-positive-tumor-patients-100481440","NCT05549024","68Ga-RM26-RGD PET\u002FCT Imaging in the GRPR and αvβ3 Positive Tumor Patients","Inclusion Criteria:\n\n* patients with confirmed or suspected breast\u002Fbrain\u002Fprostate cancer;\n* 68Ga-RM26-RGD and 18F-FDG(or 68Ga-RM26 or 68Ga-RGD) PET\u002FCT within 2 week;\n* signed written consent.\n\nExclusion Criteria:\n\n* pregnancy;\n* breastfeeding;\n* any medical condition that in the opinion of the investigator may significantly interfere with study compliance.",{"count":98,"type":19},90,[100],"EARLY_PHASE1","Based on the high expression of specific receptors on the surface of diseased tissues and neovascularization, noninvasive targeted molecular imaging can be used to visualize lesions in vitro by combining specific ligands labeled with short half-life isotopes. In this study, a novel dual-target imaging agent 68Ga-RM26-RGD was used for clinical study of tumor PET\u002FCT imaging to further verify its clinical application value.",[103,104,105,26],"Breast Cancer","Prostate Cancer","Brain Tumor","2024-07-03",{"date":108,"type":32},"2024-07-05",{"date":110,"type":32},"2022-08-16",{"date":112,"type":19},"2026-12-31",{"name":114,"class":39},"Peking Union Medical College Hospital"]